Literature DB >> 22461508

MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation.

Xi Wang1, Tianxiang Chen, Lin Leng, Jianqing Fan, Kai Cao, Zhaoxia Duan, Xijing Zhang, Changshun Shao, Mingmei Wu, Iman Tadmori, Tianyi Li, Li Liang, Dongming Sun, Shusen Zheng, Andreas Meinhardt, Wise Young, Richard Bucala, Yi Ren.   

Abstract

Although stem cell therapy holds promise as a potential treatment in a number of diseases, the tumorigenicity of embryonic stem cells (ESC) and induced pluripotent stem cells remains a major obstacle. In vitro predifferentiation of ESCs can help prevent the risk of teratoma formation, yet proliferating neural progenitors can generate tumors, especially in the presence of immunosuppressive therapy. In this study, we investigated the effects of the microenvironment on stem cell growth and teratoma development using undifferentiated ESCs. Syngeneic ESC transplantation triggered an inflammatory response that involved the recruitment of bone marrow (BM)-derived macrophages. These macrophages differentiated into an M2 or angiogenic phenotype that expressed multiple angiogenic growth factors and proteinases, such as macrophage migration inhibitory factor (MIF), VEGF, and matrix metalloproteinase 9, creating a microenvironment that supported the initiation of teratoma development. Genetic deletion of MIF from the host but not from ESCs specifically reduced angiogenesis and teratoma growth, and MIF inhibition effectively reduced teratoma development after ESC transplantation. Together, our findings show that syngeneic ESC transplantation provokes an inflammatory response that involves the rapid recruitment and activation of BM-derived macrophages, which may be a crucial driving force in the initiation and progression of teratomas. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461508      PMCID: PMC3779606          DOI: 10.1158/0008-5472.CAN-11-3247

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment.

Authors:  Jürgen Bernhagen; Regina Krohn; Hongqi Lue; Julia L Gregory; Alma Zernecke; Rory R Koenen; Manfred Dewor; Ivan Georgiev; Andreas Schober; Lin Leng; Teake Kooistra; Günter Fingerle-Rowson; Pietro Ghezzi; Robert Kleemann; Shaun R McColl; Richard Bucala; Michael J Hickey; Christian Weber
Journal:  Nat Med       Date:  2007-04-15       Impact factor: 53.440

2.  Variation in the safety of induced pluripotent stem cell lines.

Authors:  Kyoko Miura; Yohei Okada; Takashi Aoi; Aki Okada; Kazutoshi Takahashi; Keisuke Okita; Masato Nakagawa; Michiyo Koyanagi; Koji Tanabe; Mari Ohnuki; Daisuke Ogawa; Eiji Ikeda; Hideyuki Okano; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2009-07-09       Impact factor: 54.908

3.  Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats.

Authors:  Dali Yang; Zhi-Jian Zhang; Michael Oldenburg; Melvin Ayala; Su-Chun Zhang
Journal:  Stem Cells       Date:  2007-10-18       Impact factor: 6.277

Review 4.  The role of CXC chemokines and their receptors in cancer.

Authors:  Jo Vandercappellen; Jo Van Damme; Sofie Struyf
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

5.  Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth.

Authors:  Susanna Purhonen; Jarmo Palm; Derrick Rossi; Nina Kaskenpää; Iiro Rajantie; Seppo Ylä-Herttuala; Kari Alitalo; Irving L Weissman; Petri Salven
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

6.  Generation of mouse induced pluripotent stem cells without viral vectors.

Authors:  Keisuke Okita; Masato Nakagawa; Hong Hyenjong; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Science       Date:  2008-10-09       Impact factor: 47.728

7.  Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression.

Authors:  Hiroshi Fujimoto; Takafumi Sangai; Genichiro Ishii; Akashi Ikehara; Takeshi Nagashima; Masaru Miyazaki; Atsushi Ochiai
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

8.  Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

Authors:  Robert D Loberg; Chi Ying; Matt Craig; Lashon L Day; Erin Sargent; Chris Neeley; Kirk Wojno; Linda A Snyder; Li Yan; Kenneth J Pienta
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

10.  The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response.

Authors:  Ralf Dressel; Jan Schindehütte; Tanja Kuhlmann; Leslie Elsner; Peter Novota; Paul Christian Baier; Arne Schillert; Heike Bickeböller; Thomas Herrmann; Claudia Trenkwalder; Walter Paulus; Ahmed Mansouri
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

View more
  22 in total

1.  Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2016-05-11       Impact factor: 9.306

2.  Macrophages in spinal cord injury: phenotypic and functional change from exposure to myelin debris.

Authors:  Xi Wang; Kai Cao; Xin Sun; Yongxiong Chen; Zhaoxia Duan; Li Sun; Lei Guo; Paul Bai; Dongming Sun; Jianqing Fan; Xijing He; Wise Young; Yi Ren
Journal:  Glia       Date:  2014-11-28       Impact factor: 7.452

3.  Neural Stem Cell-Conditioned Medium Suppresses Inflammation and Promotes Spinal Cord Injury Recovery.

Authors:  Zhijian Cheng; Dale B Bosco; Li Sun; Xiaoming Chen; Yunsheng Xu; Wenjiao Tai; Ruth Didier; Jinhua Li; Jianqing Fan; Xijing He; Yi Ren
Journal:  Cell Transplant       Date:  2016-10-12       Impact factor: 4.064

4.  Macrophage Migration Inhibitory Factor Limits Renal Inflammation and Fibrosis by Counteracting Tubular Cell Cycle Arrest.

Authors:  Sonja Djudjaj; Ina V Martin; Eva M Buhl; Nina J Nothofer; Lin Leng; Marta Piecychna; Jürgen Floege; Jürgen Bernhagen; Richard Bucala; Peter Boor
Journal:  J Am Soc Nephrol       Date:  2017-08-11       Impact factor: 10.121

Review 5.  Stromal-dependent tumor promotion by MIF family members.

Authors:  Robert A Mitchell; Kavitha Yaddanapudi
Journal:  Cell Signal       Date:  2014-09-30       Impact factor: 4.315

6.  Pleiotropic role of macrophage migration inhibitory factor in cancer.

Authors:  Maheedhara R Guda; Matthew A Rashid; Swapna Asuthkar; Anvesh Jalasutram; John L Caniglia; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

7.  Characterization of Neospora caninum macrophage migration inhibitory factor.

Authors:  Guanggang Qu; Raymond Fetterer; Mark Jenkins; Lin Leng; Zhiqiang Shen; Charles Murphy; Wenyu Han; Richard Bucala; Wenbin Tuo
Journal:  Exp Parasitol       Date:  2013-07-11       Impact factor: 2.011

8.  Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor.

Authors:  Kavitha Yaddanapudi; Kalyani Putty; Beatriz E Rendon; Gwyneth J Lamont; Jonathan D Faughn; Abhay Satoskar; Amanda Lasnik; John W Eaton; Robert A Mitchell
Journal:  J Immunol       Date:  2013-02-06       Impact factor: 5.422

Review 9.  25 Years On: A Retrospective on Migration Inhibitory Factor in Tumor Angiogenesis.

Authors:  Jason A Chesney; Robert A Mitchell
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

10.  MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation.

Authors:  Kavitha Yaddanapudi; Beatriz E Rendon; Gwyneth Lamont; Eun Jung Kim; Numan Al Rayyan; Jamaal Richie; Sabrin Albeituni; Sabine Waigel; Ashley Wise; Robert A Mitchell
Journal:  Cancer Immunol Res       Date:  2015-11-24       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.